PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals
- Biomater. Res., May 31 2024, 12 (1) | https://doi.org/10.1186/s40364-024-00604-x